DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Information source: Threshold Pharmaceuticals
Information obtained from ClinicalTrials.gov on December 08, 2011
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Soft Tissue Sarcoma

Intervention: TH-302 in Combination with Doxorubicin (Drug); Doxorubicin (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Threshold Pharmaceuticals

Official(s) and/or principal investigator(s):
William Tap, MD, Principal Investigator, Affiliation: Memorial Sloan-Kettering Cancer Center

Summary

The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma.

Clinical Details

Official title: A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Efficacy of TH-302 in combination with doxorubicin

Secondary outcome: Safety of TH-302 in combination with doxorubicin in subjects with locally advanced unresectable or metastatic soft tissue sarcoma compared with doxorubicin alone

Detailed description: TH-302 is designed to target the hypoxic regions of tumors which are generally located distant from tumor vessels. Doxorubicin has poor tissue penetration and targets the regions of tumors that are located in proximity to the tumor vessels. The presence of hypoxia in solid tumors is associated with a more malignant phenotype and resistance to chemotherapy. The hypoxia-activated prodrug, TH-302, is designed to selectively target the hypoxic microenvironment. Soft tissue sarcomas have evidence supporting the presence of hypoxia based on pO2 histography, F-MISO and gene expression profiling. There is an absence of therapeutic options for subjects with soft tissue sarcoma. Combining doxorubicin with TH-302 may enable the targeting of both the normoxic and hypoxic regions of soft tissue sarcoma.

Eligibility

Minimum age: 15 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male or female ≥ 15 years of age

- Ability to understand the purposes and risks of the study and has signed or, if

appropriate, the subject's parent or legal guardian has signed a written informed consent form approved by the investigator's IRB/Ethics Committee

- Pathologically confirmed diagnosis of soft tissue sarcoma of the following

histopathologic types:

- Synovial sarcoma

- High grade fibrosarcoma

- Undifferentiated sarcoma; sarcoma not otherwise specified (NOS)

- Liposarcoma

- Leiomyosarcoma (excluding GIST)

- Angiosarcoma (excluding Kaposi's sarcoma)

- Malignant peripheral nerve sheath tumor

- Pleomorphic Rhabdomyosarcoma

- Myxofibrosarcoma

- Epithelioid sarcoma

- Undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma (MFH)

(including pleomorphic, giant cell, myxoid and inflammatory forms)

- Locally advanced unresectable or metastatic disease with no standard curative therapy

available and for whom treatment with single agent doxorubicin is considered appropriate.

- Recovered from reversible toxicities of prior therapy

- Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1. 1

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Life expectancy of at least 3 months

- Acceptable liver, renal, hematological and cardiac function

- All women of childbearing potential must have a negative serum pregnancy test and all

subjects must agree to use effective means of contraception

Exclusion Criteria:

- Prior systemic therapy for advanced or metastatic disease (neoadjuvant therapy

followed by surgical resection and adjuvant therapy permitted)

- Low grade tumors according to standard grading systems

- Prior therapy with ifosfamide or cyclophosphamide or other nitrogen mustards

- Prior therapy with an anthracycline or anthracenedione

- Prior mediastinal/cardiac radiotherapy

- Current use of drugs with known cardiotoxicity or known interactions with doxorubicin

- Anti-cancer treatment with radiation therapy, neoadjuvant or adjuvant chemotherapy,

targeted therapies, immunotherapy, hormones or other antitumor therapies within 4 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C)

- Significant cardiac dysfunction precluding treatment with doxorubicin

- Seizure disorders requiring anticonvulsant therapy unless seizure-free for the last

year

- Known brain metastases (unless previously treated and well controlled for a period of

≥ 3 months)

- Previously treated malignancies, except for adequately treated non-melanoma skin

cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years

- Severe chronic obstructive or other pulmonary disease with hypoxemia or in the

opinion of the investigator any physiological state likely to cause normal tissue hypoxia

- Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without

complete recovery

- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic

therapy

- Prior therapy with a hypoxic cytotoxin

- Subjects who participated in an investigational drug or device study within 28 days

prior to study entry

- Known infection with HIV, hepatitis B, or hepatitis C

- Subjects who have exhibited allergic reactions to a structural compound similar to

TH-302,doxorubicin or their excipients

- Females who are pregnant or breast-feeding

- Concomitant disease or condition that could interfere with the conduct of the study,

or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study

- Unwillingness or inability to comply with the study protocol for any reason

Locations and Contacts

Arizona Cancer Center, Tucson, Arizona 85719, United States; Not yet recruiting
Sue Jordan, Phone: 520-694-9056, Email: sdeporter@azcc.arizona.edu
Lee Cranmer, MD, Principal Investigator

Sarcoma Oncology Center, Santa Monica, California 90403, United States; Recruiting
Victoria Chua, Phone: 310-552-9999
Sant P Chawla, MD, Principal Investigator

Stanford Comprehensive Cancer Center, Stanford, California 94305, United States; Not yet recruiting
Maria Ahern, Phone: 650-725-6413, Email: mahern@stanford.edu
Kristen Ganjoo, ME, Principal Investigator

Additional Information

Starting date: September 2011
Last updated: December 2, 2011

Page last updated: December 08, 2011

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012